S1314
Clinical - Urology
ESTRO 2026
Conclusion: Analysis of nationwide registry data demonstrated that the incidence of severe gastrointestinal complications after prostate radiotherapy in the Czech Republic is below 5 % within five years of treatment. Stereotactic radiosurgery appears to provide the most favourable toxicity profile, with a significantly lower rate of recurrent bleeding events compared to other modalities. Institutional practice patterns may play a greater role in complication rates than the specific radiotherapy technique used. References: Lin D.Y., W. L. (2000). Semiparametric Regression for the Mean and Rate Functions of Recurrent Events. Journal of the Royal Statistical Society. Series B (Statistical Methodology), Vol. 62, No. 4, pages 711- 730.Andersen P.K., G. R. (December 1982). Cox s Regression Model for Counting Processes: A Large Sample Study. The Annals of Statistics, Vol. 10, No. 4, pages 1100-1120. Keywords: Prostate radiotherapy, Rectum toxicity PSMA PET/CT for the Detection of Prostate Cancer Biochemical Recurrence after Primary Radiation Therapy: Is It Time to Review the Phoenix Criteria? Rosario Mazzola 1,2 , Carlo Vallone 3 , Priscilla Guglielmo 1,4 , Sara Damiani 1 , Jelena Jandric 5 , Andrea Brignoli 2 , Manuela Marenco 5 , Francesco Martino 2 , Luciana Di Cristina 6 , Ciro Franzese 1,6 , Laura Evangelista 1,5 1 Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy. 2 Department of Radiotherapy, Humanitas Gavazzeni, Bergamo, Italy. 3 Department of Advanced Biomedical Sciences, University of Naples "Federico II", Naples, Italy. 4 Nuclear Medicine Unit, Humanitas Gavazzeni, Bergamo, Italy. 5 Nuclear Medicine Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy. 6 Radiotherapy and Radiosurgery Department, IRCCS Humanitas Research Hospital, Rozzano, Italy Purpose/Objective: Biochemical recurrence (BCR) in prostate cancer (PCa) after definitive radiotherapy (RT) is defined by a PSA rise ≥ 2.0 ng/mL (Phoenix criteria, Pc). In clinical Digital Poster Highlight 4944 settings, PSMA PET/CT has demonstrated the ability to identify recurrent disease in case of PSA values remain below this threshold. This retrospective, multicentre study evaluated PSMA PET/CT in patients with rising PSA below the Phoenix-threshold. Material/Methods: We retrospectively analysed PCa patients who underwent PSMA PET/CT for rising PSA below Pc in the period 2020-2023. Patients with prior recurrence
with a statistically superior outcome. Significant differences were observed between SBRT and IMRT/VMAT (p < 0.0001), SBRT and 3D-CRT (p < 0.0001), and SBRT and proton therapy (p < 0.0001), consistently favouring SBRT. Many significant differences were found between hospitals, regardless of whether they used the same or different radiotherapy techniques. Significant differences in mortalities and differences between patients and the control group were also observed.
Made with FlippingBook - Share PDF online